FIELD: chemistry.
SUBSTANCE: present invention relates to novel glucagon compounds containing three or more negatively charged fragments, where one of said negatively charged fragments is located distally from a lipophilic fragment. The compounds have high physical stability in a solution and improved solubility at neutral pH values.
EFFECT: invention relates to treatment methods and to the use of said compounds to produce drugs for treating hypertension, diabetes and obesity, as well as various diseases or conditions associated with hyperglycaemia, diabetes and obesity.
27 cl, 2 tbl, 20 dwg, 108 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
| DOUBLE ACYLATED GLP-1 DERIVATIVES | 2012 |
|
RU2602601C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| ANALOGUES OF EGF(A) WITH SUBSTITUENTS-FATTY ACIDS | 2017 |
|
RU2747877C2 |
| SELECTIVE PYY COMPOUNDS AND USES THEREOF | 2014 |
|
RU2678312C1 |
| SELECTIVE COMPOUNDS OF YY PEPTIDE AND USE THEREOF | 2016 |
|
RU2726777C2 |
| INSULIN DERIVATIVES CONTAINING ADDITIONAL DISULFIDE BONDS | 2011 |
|
RU2598273C2 |
| FGF21 DERIVATIVES AND USE THEREOF | 2015 |
|
RU2729011C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
